after the use of 2-chloroprocaine for obstetric epidural analgesia. Several years later, the repeated injection of 5% lidocaine through spinal microcatheters was found to produce the syndrome of "transient neurologic symptoms" (TNS) after recovery from otherwise uncomplicated continuous subarachnoid anesthetics. Affected patients reported pain and dysesthesias radiating from the lower back into the lower extremities with symptoms generally waning after 1 to 4 weeks. Far less frequently, the subarachnoid administration of 5% lidocaine was followed by more severe lumbosacral radiculopathies such as cauda equina syndrome with symptoms including paresthesias, loss of lower extremity motor function, and fecal and urinary incontinence. 4 Determinants of Neurotoxicity. In the case of 2-chloroprocaine, the original commercial preparation was stabilized with a relatively low pH and bisulfite as a preservative. Most experimental investigations suggested that the bisulfite and acidic pH were the neurotoxic culprits, although one study found bisulfite to be actually neuroprotective against 2-chloroprocaine toxicity. Published clinical reports are now supporting the contention that preservative-free 2-chloroprocaine (at a more neutral pH) is a safe and effective choice for subarachnoid administration. 3, 5 With lidocaine, both pharmacologic and technical factors may contribute to local neurotoxicity. In vitro experiments indicate that lidocaine itself may have a greater propensity for neurotoxicity than other LAs used for spinal anesthesia. 6 Authors of clinical reports have also concluded that the risk of TNS and more severe radiculopathies is up to an order of magnitude greater with lidocaine (2% to 5%) than with other subarachnoid LAs. [7] [8] [9] The administration of lidocaine 5% through spinal "microcatheters" gained shortlived popularity, which was terminated by a flurry of case reports of associated cauda equina syndromes. It was speculated that the "microspinal" catheter reduced the mixing of LAs within spinal fluid, exposing nerve roots to relatively high concentrations of the LA, greater than would be present after injections through the larger orifice of a conventional spinal needle. Other reports have suggested that subarachnoid lidocaine is more likely to induce TNS when patient positioning (e.g., lithotomy or for knee arthroscopy) puts tension on the cauda equina. 4, 10 Curiously, a large clinical series of mepivacaine subarachnoid anesthetics found no impact of patient positioning on the incidence of TNS 11 (Table 1) . Pharmacologic Options for Subarachnoid Anesthesia. Before its being associated with TNS, lidocaine was considered the ideal agent for brief spinal anesthetics. Tetracaine and bupivacaine have extensive histories of safety and efficacy, but their relatively prolonged duration of action is not optimal for ambulatory procedures. Subarachnoid prilocaine reportedly provides anesthesia of relatively brief duration, with a low associated incidence of TNS, but is not available in the United States in other than a topical form. 8 The clinical effect of spinal procaine is short-lived, but the reported incidence of associated nausea and vomiting is excessive. 12 It was widely, although wrongly, assumed that the reported cases of prolonged paralysis after labor epidural analgesia with 2-chloroprocaine all resulted from accidental subarachnoid injections. 13 It is, therefore, ironic that this same LA in preservative-free form is emerging as a potentially safer alternative to subarachnoid lidocaine. Yoos and Kopacz have published an initial clinical series of 122 spinal anesthetics in which preservative-free 2-chloroprocaine (usually 2% plain) was administered in doses of 30 to 40 mg (1.5 to 2 mL). Surgical anesthesia was reliably produced and no cases of TNS were observed. 10 With a clinical experience that now extends to several hundred cases, these authors have detected a low incidence of TNS and no persistent radiculopathies.
Mepivacaine, an intermediate-duration LA, traditionally used for peripheral nerve blocks, has also been studied for subarachnoid administration. In one study, TNS was
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TASCH AND BUTTERWORTH reported in 30 of 100 patients receiving hyperbaric mepivacaine 4% in an 80-mg dose (2 mL). 14 However, in a more recent, far larger study of patients receiving isobaric mepivacaine 1.5% in doses of 30 to 70 mg, only 78 of 1,210 (6.4%) patients reported subsequent TNS. The reliability and duration of spinal mepivacaine in this series were suitable for ambulatory procedures 11 (Table 1) .
Systemic Forms of Toxicity

Central Nervous System Toxicity
As systemic concentrations of any LA rise, the possibility of central nervous system (CNS) side effects increases. Within the brain, inhibitory pathways are the first to be suppressed. These pathways are largely dependent on the functioning of γ-aminobutyric acid (GABA) receptors, the site to which ethanol, propofol, benzodiazepines, and barbiturates bind. Activated GABA receptors stimulate the intracellular movement of chloride ions, an effect that is antagonized by LAs. LAs may also stimulate CNS excitatory mechanisms by activating N-methyl-D-aspartate (NMDA) receptors. 15 CNS disinhibition produces early complaints that include a metallic taste, tinnitus, and tremulousness and can culminate in tonic-clonic seizures. At still higher systemic concentrations, excitatory pathways are also suppressed, producing coma and depressed respiration. If not promptly managed, severe CNS toxicity can produce hypoxia and acidosis, among other complications.
Cardiovascular Toxicity
With the exception of bupivacaine, the systemic concentrations of LA required to produce severe cardiovascular (CV) toxicity reliably and significantly exceed those producing convulsions. Severe CNS toxicity not only precedes CV collapse (in most cases), but can also exacerbate it by creating a milieu of hypoxia, hypercarbia, and acidosis. The most worrisome manifestations of CV toxicity are arrhythmias and myocardial depression. Arrhythmogenesis. LAs have been used as antiarrhythmic agents for 50 years. Nevertheless, the more potent LAs (which are generally more lipophilic and longer-acting) can disrupt the electrical functions of the heart in a wide variety of ways. LAs can inhibit conduction through the sinoatrial (SA) and atrioventricular (AV) nodes, prolong the PR interval and QRS complex duration, and generate AV block of varying degrees. CV toxicity can include both bradyarrhythmias and reentry tachyarrhythmias such as ventricular tachycardia (VT) or fibrillation (VF). 16, 17 Although LA actions, both therapeutic and toxic, are commonly attributed to the blockade of voltage-gated sodium (Na) channels, these drugs also alter potassium (K) and calcium (Ca) ion fluxes. Although of the 9 Na channel gene products in mammals, only one form (Na v 1.5) is found in cardiac tissue, LA-induced Na channel blockade in myocardial cells is inhomogeneous, creating differing degrees of conduction block throughout the heart. 18 This situation favors reentry arrhythmias. Na channels exist in the open, closed, or inactivated state, the last of which is favored by membrane depolarization. Action potentials are prolonged in myocardial as compared with neural cells. Bupivacaine has been found to bind most avidly to Na channels in the open or inactivated states, a characteristic that could contribute to its propensity to induce severe CV derangements along with or before CNS toxicity. Toxic systemic levels of LAs block K channels as well. This channel effect further prolongs the duration of myocardial action potentials, increasing the affinity of bupivacaine for Na channels. K channel inhibition exacerbates the inhomogeneity of myocardial depolarization and repolarization, increasing the likelihood of reentrant tachyarrhythmias. 19, 20 Furthermore, investigators have demonstrated that the direct exposure of certain regions of the brain to LAs can generate hypotension and various brady-and tachyarrhythmias. 16, 21 Myocardial Depression. Systemic manifestations of LA toxicity can also include profound depression of myocardial contractility through a variety of possible pathophysiological mechanisms. Voltage-gated Ca channels are subject to binding and inhibition by LAs. The affinity of LAs for Ca channels is generally proportional to their lipid solubility, anesthetic potency and duration, and negative inotropic potency. At the myocardial intracellular level, LAs also inhibit Ca ion release from the sarcoplasmic reticulum.
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LAs may produce myocardial depression by mechanisms independent of Ca channels and ion movement. The more potent LAs inhibit β-adrenergic receptor binding and adenyl cyclase activity. As a consequence, LAs have also been shown to reduce the intracellular synthesis of cyclic adenosine monophosphate (cAMP), both at baseline and in response to epinephrine, in laboratory models. Thus, LA toxicity may impair the inotropic response to both endogenous and therapeutically administered catecholamines. 22, 23 Investigators have also found that the more potent LAs inhibit the oxidative phosphorylation of adenosine diphosphate to adenosine triphosphate (ATP), potentially impairing myocardial energetics. Bupivacaine, in particular, suppresses the synthesis of ATP in isolated mitochondria, whereas the pretreatment of isolated myocardial tissue with ATP reduces the bupivacaine-induced depression of contractile function. The relative contribution of these various potential mechanisms to recalcitrant bupivacaine-induced myocardial depression is as yet undetermined.
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Determinants of Systemic Toxicity
Pharmacokinetic Factors
The likelihood and intensity of systemic drug toxicity generally varies with the circulating concentration of the drug in a form that is not protein-bound. LAs are, as a rule, not (intentionally) administered directly into the bloodstream, so systemic drug levels are the result of interplay among dosage, additives, and site of injection. Attempts to define "safe maximal" LA doses are unlikely to yield clinically meaningful results, especially if the site of administration is disregarded. Barring accidental intravascular injection, the systemic uptake of LAs is primarily a function of the vascularity of the tissue into which the drug is placed. For any given drug and dose, the fastest systemic uptake can be found after intratracheal administration. Progressively lower levels can be found after paracervical and intercostal administration, epidural, peripheral nerve plexus than subarachnoid injections. 26 Aside from limiting the LA dose to a presumably "safe" but effective level, the technique most frequently used to limit systemic drug concentrations is the coadministration of a vasoconstricting agent, most commonly epinephrine. In a concentration of 5 µg/mL (1:200,000), epinephrine markedly reduces the maximal systemic concentrations of LAs measured after subcutaneous infiltration or superficial cervical plexus injection. The reduction of systemic uptake is somewhat less, but still substantial, with intercostal, epidural, and peripheral nerve plexus injection. 26 Some clinicians will refrain from administering epinephrine to patients with such conditions as coronary atherosclerosis. However, one study of patients receiving cervical plexus block for carotid endarterectomy indicated that the addition of epinephrine to the LA solution had no impact on heart rate or the on the perioperative incidence of myocardial ischemia or tachyarrhythmias detected by Holter monitoring. 27 Patient-specific conditions can influence the systemic uptake and toxicity of appropriately administered LAs. Conditions that alter the binding of amide-linked LAs to albumin and to α 1 -acid glycoprotein (AGP) will affect the concentration of drug found in its free, pharmacologically active form. In the second and third trimesters of pregnancy, elevated cardiac output tends to accelerate the vascular absorption of drugs from tissues. 28 In addition, the gravid uterus causes epidural venous distention, decreasing the volume of LA required to achieve a given level of neural blockade and possibly expanding the vascular surface through which drugs may pass into the systemic circulation. 29 Pregnancy (and acidemia) diminish the protein binding of bupivacaine, but probably not to a clinically important degree. 30, 31 Independently of pharmacokinetics, gestation is also thought to increase the neuronal and myocardial sensitivity to some LAs, possibly as a result of the effects of progesterone. 32, 33 Renal failure influences LA pharmacokinetics in ways that may oppose each other. If cardiac output rises to compensate for anemia, systemic uptake of LA from tissues tends to increase, shortening the duration of local and regional anesthesia. 28 Renal failure also reduces the excretion and metabolism of LAs, but uremia increases their binding affinity for AGP, reducing the unbound fraction of the drugs.
Although ester-linked LAs (procaine, 2-chloroprocaine, tetracaine) are degraded by plasma esterases, amide-linked LAs are eliminated mainly through hepatic metabolism. Circulating levels of the amide agents can thus be prolonged when hepatic function is markedly impaired. Heart failure, β-adrenergic-blocking drugs, and aging can retard the clearance of these drugs by reducing cardiac output and hepatic perfusion. 26 Circulating concentrations of ester LAs would likely be prolonged by deficiency or inhibition of cholinesterase, but there are no data to confirm this supposition.
Pharmacodynamic Factors
The common structural features of LAs are a hydrocarbon chain and an aromatic ring connected by either an ester or an amide linkage. In general, LAs of increasing molecular weight are characterized by greater lipid solubility and duration of action. Increased lipid solubility is associated with an increased ability to permeate cellular TOXICITY OF LOCAL ANESTHETICS 169 membranes and increased binding affinity for ion channels, and this associates with increased potency for both local anesthesia and systemic toxicity. 22 Because the bupivacaine molecule includes an asymmetric (chiral) carbon, there are two stereoisomers of this anesthetic, with the (S−) enantiomer (levobupivacaine) generally considered to bear a lesser propensity to induce severe systemic toxicity than the (R+) enantiomer or the standard racemic mixture. Ropivacaine, a derivative of bupivacaine, is also commercially produced in the form of its (S−) enantiomer. 34 Although levobupivacaine appears to be equipotent (at nerve block) to the (R+) isomer and to racemic bupivacaine, the relative potency of ropivacaine versus bupivacaine has been debated. With no universally accepted standard for LA potency (as would be analogous to MAC for general anesthetics), different investigators have determined that ropivacaine is either equipotent to the bupivacaines or roughly 40% less potent. [35] [36] [37] Thus, comparative studies of LA toxicity have been predicated on different definitions of what constitutes "equivalent" doses of these agents.
Comparative Toxicity-Central Nervous System. The vast majority of investigations into the comparative systemic effects of LAs have addressed CV toxicity, but CNS toxicity has also been studied. In general, the long-acting amide-linked LAs manifest approximately four times the epileptogenic potency of lidocaine, comparable to their anesthetic potencies and with the same rank order. Investigators have generally found the S(−) enantiomers to be less potent than racemic bupivacaine at producing convulsions. 16 In one study, the epileptogenic dose of ropivacaine significantly exceeded that of bupivacaine in awake and in thiopental-anesthetized rats. Other researchers determined that the convulsive doses of both levobupivacaine and ropivacaine in anesthetized rats exceeded that of racemic bupivacaine. 38 As has been noted in case reports, bupivacaine can sometimes produce CV collapse without first producing obvious signs of CNS toxicity.
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Comparative Toxicity-Arrhythmias. Even at presumably equipotent doses or plasma concentrations, bupivacaine and lidocaine differ dramatically in their effects on cardiac rhythm. Elevated systemic levels of bupivacaine tend to induce potentially lethal arrhythmias, whereas lidocaine is, of course, a commonly used antiarrhythmic agent. Differences in channel-binding characteristics may help explain this difference as well as arrhythmogenic disparities among the longer-acting LAs.
Although all LAs studied have a high affinity for myocardial Na channels during systole (when channels are open or inactivated), lidocaine dissociates promptly from these channels during diastole, whereas bupivacaine remains as a persistent (and clinically unwelcome) occupant. (R+) bupivacaine also binds more avidly to these channels during diastole than does the (S−) enantiomer. 17, 40 In addition, (R+) bupivacaine binds more avidly to K channels than does (S−) bupivacaine, with the affinity of ropivacaine being less than that of either bupivacaine isomer. 41, 42 Persistent inhibition of myocardial ion conductance could contribute to disruptions of impulse conduction and of cardiac rhythm.
In studies on isolated mammalian hearts, (R+) bupivacaine was found to be more consistently and profoundly arrhythmogenic than levobupivacaine. [43] [44] [45] In conscious sheep, the intravenous administration of racemic bupivacaine commonly generated potentially lethal ventricular arrhythmias, whereas intravenous levobupivacaine induced nothing worse than brief runs of VT. 46 Such reports would suggest a significant difference between the bupivacaine isomers in terms of systemic CV toxicity.
Laboratory reports comparing ropivacaine with bupivacaine have generally favored ropivacaine. Studies in isolated rodent hearts determined that ropivacaine was significantly less arrhythmogenic than racemic bupivacaine. 39, 47 In anesthetized rats, ropivacaine was less arrhythmogenic than levobupivacaine, which in turn was less arrhythmogenic than racemic bupivacaine 38 ( Fig. 1) . Studies of anesthetized dogs and pigs have FIG. 1. Cumulative dose and plasma concentrations of bupivacaine, levobupivacaine, and ropivacaine at onset of seizure activity, dysrhythmia, and asystole. Significant difference at P < 0.05 compared with bupivacaine. †Significant difference at P < 0.05 compared with levobupivacaine. The cumulative dose producing dysrhythmias was significantly higher than the cumulative dose producing seizures for ropivacaine and levobupivacaine, but not for bupivacaine. also usually indicated that ropivacaine has less propensity to produce lethal ventricular arrhythmias than racemic bupivacaine, with levobupivacaine being intermediate between these two agents. 16, 41, 48, 49 Comparative Toxicity-Myocardial Depression. At a sufficient concentration, all LAs will depress myocardial contractility. As is the case with arrhythmogenesis, ropivacaine and levobupivacaine have generally been found to be less potent at producing negative inotropic effects than racemic bupivacaine. In disparate studies conducted on isolated rodent hearts or papillary muscle, (S−) bupivacaine was less potent at producing myocardial depression than the (R+) isomer, whereas ropivacaine was less potent than racemic bupivacaine. 47 Experiments performed on awake and anesthetized rats indicated that (R+) bupivacaine was a far more potent negative inotrope than either (S−) bupivacaine or ropivacaine. In anesthetized dogs, both (S−) and racemic bupivacaine were more potent negative inotropes than ropivacaine. 39, 50 Similar results were found when the LAs were injected into the coronary arteries of awake sheep. 51 The consensus of such research generally indicates a rank order of myocardial depressant potency of racemic bupivacaine > levobupivacaine > ropivacaine. Conclusions regarding clinical safety must, however, include some consideration of the aforementioned questions regarding the relative anesthetic potency of ropivacaine as compared with the bupivacaines.
Comparative Toxicity-Cardiovascular Collapse and Resuscitation. Depending on the agent studied and the experimental conditions, the terminal event of LA toxicity can be either a lethal arrhythmia or intractable hypotension. Differences among the agents' inherent toxicities may be reflected in the susceptibility of LA-induced CV collapse to successful resuscitation. In the intact subject, the occurrence of convulsions can alter the resuscitative milieu with adrenergic stimulation, hypoxia, acidosis, and hypercarbia.
In experimental LA-induced CV collapse, the required resuscitative dose of epinephrine in rats was lower in the presence of ropivacaine than with either levobupivacaine or bupivacaine 38 (Table 2 ). In a canine study, a significantly larger dose of ropivacaine could be infused before incurring hemodynamic collapse than was true for either levobupivacaine or racemic bupivacaine. Nine of 10 dogs could be resuscitated from severe ropivacaine-induced CV toxicity compared with seven of 10 after levobupivacaine and five of 10 after racemic bupivacaine. (With the limited number of dogs studied, these differences were not statistically significant.) In this study, epinephrine induced VF in four of nine dogs studied after bupivacaine infusion compared with two of 10 after levobupivacaine and zero of eight after ropivacaine 48 (Table 3 ). The reports cited tend to validate the hope that the newer potent LAs will prove to be safer in patients than racemic bupivacaine.
Although LA-induced seizures are inherently undesirable, their occurrence can serve as a useful warning of impending hemodynamic calamity. In some clinical reports of severe systemic bupivacaine toxicity, CV collapse occurred without a CNS prodrome. Laboratory studies in both awake and anesthetized rats demonstrated a significant difference between the epileptogenic and hemodynamically lethal doses of ropivacaine and levobupivacaine, but not of racemic bupivacaine. Other authors concur that the CV:CNS margin of "safety" (or margin of warning) is insignificant for bupivacaine, significant for levobupivacaine, and larger for ropivacaine. 16, 38, 39 Besides being often unheralded by convulsions, severe bupivacaine-induced CV toxicity has frequently proven impossible or exceedingly difficult to treat. Clinical reports of CV toxicity with ropivacaine and levobupivacaine have begun to appear and are far more encouraging. In one case, the accidental systemic administration of 140 mg levobupivacaine produced no sequelae. In another, 125 mg intravenous levobupivacaine led to uncomplicated episodes of hypotension, which were readily reversed with epinephrine and a subsequent norepinephrine infusion. 52, 53 Four cases of severe ropivacaine-induced CV toxicity have been reported with ultimately favorable outcomes. In two cases, resuscitation from cardiac arrest was readily achieved with either 1 mg epinephrine or with closed chest compression and 6 mg ephedrine. A case of profound bradycardia was corrected with 10 mg ephedrine and 0.1 mg epinephrine. A case of VF promptly resolved with closed chest compression alone. 34, [54] [55] [56] Although too few in number to be definitive, these case reports contrast favorably with many of those concerning bupivacaine-induced CV toxicity.
Clinical Management of Systemic Toxicity
Prevention
The standard measures to avert systemic LA toxicity include proper technique for injection (including fractionated dosing and frequent aspiration for blood when a vessel is near), appropriate drug and dose selection, and vigilance for signs or symptoms of drug reactions. When relatively large volumes of anesthetic solution are to be injected, for example, into the epidural space, the addition of epinephrine may yield hemodynamic evidence of intravascular injection. Increases in heart rate or blood pressure may be elicited by small test doses before the full intended volume is delivered. Cumulative Dose to Cardiovascular Collapse (mg/kg)* These changes may, however, be masked by the CV responses to uterine contractions in the laboring parturient.
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Treatment of Central Nervous System Toxicity
Besides their inherent dangers, seizures may both contribute to and precede CV disturbances by causing hypoxia, hypercarbia, acidosis, and hyperkalemia. Initial concerns include the establishment of a secure airway, maintenance of oxygenation and gas exchange, and prevention of physical trauma. If the convulsion persists, management can include modest doses of thiopental, propofol, or a benzodiazepine.
Treatment of Cardiovascular Toxicity
Hemodynamic collapse from any cause should be addressed with advanced cardiac life support (ACLS) standards. Oxygenation and ventilation must be assured, then electrical and pharmacologic interventions applied as needed to restore cardiac rhythm and adequate perfusion pressures to the myocardium and other vital organs. The continuing presence of toxic systemic levels of a LA can attenuate the effects of conventional resuscitative agents.
Arrhythmias. Although lidocaine has been the traditional first-line agent in the usual management of ventricular ectopy and arrhythmias, the use of one local anesthetic to treat toxic systemic effects of another has been challenged. 26, 53 Animal studies may shed some light on this issue. In isolated rabbit hearts perfused with a toxic concentration of bupivacaine, the addition of either lidocaine or phenytoin (both of which block Na channels) exacerbated intraventricular conduction delay. 57 In a study performed on anesthetized swine, the coadministration of lidocaine increased the incidence of convulsions and asystole but reduced the incidence of ventricular tachyarrhythmias. 58 In the absence of strong evidence-based guidance, and with no documented advantage to compounding the possible toxicities of different LAs, amiodarone would appear to be a better antiarrhythmic option than lidocaine.
Cardiovascular Depression. Hemodynamic collapse resulting from bupivacaine intoxication is notoriously resistant to epinephrine-based resuscitation. Regardless of the etiology for cardiac arrest, successful resuscitation rests on the maintenance of coronary perfusion pressure, which in turn requires adequate peripheral vasomotor tone. In correcting bupivacaine toxicity, myocardial perfusion must generally be sustained for a time sufficient to allow the drug to be eluted from the myocardium. 48 The α-adrenergic effects of epinephrine powerfully promote peripheral vasoconstriction. The positive inotropic effects of β-adrenergic agonists may also be beneficial, but the increase in myocardial oxygen consumption resulting from inotropic and chronotropic stimulation may exceed supply. In addition, combination of epinephrine with toxic levels of bupivacaine may lead to lethal ventricular tachyarrhythmias. In comparison to epinephrine, with norepinephrine, the balance of effects is tilted more toward the α-adrenergic, vasoconstrictor side. Thus, norepinephrine might potentially be the more useful of the two catecholamines in cardiac resuscitation from bupivacaine toxicity or other causes. 59 Vasopressin is another agent with predominantly vasoconstrictor properties. In a study of swine subjected to electrically induced VF during the course of epidural anesthesia, resuscitation with vasopressin was associated with a greater likelihood of survival and more favorable coronary perfusion pressure and arterial pH than was seen with epinephrine 60 (Table 4) . Although this experiment did not represent systemic bupivacaine toxicity, the findings suggest the advantageous resuscitative properties of vasopressin. The guidelines for ACLS now include vasopressin as an option.
As noted earlier, toxic concentrations of potent LAs depress the intracellular synthesis of cAMP, which mediates β-adrenergic effects. Phosphodiesterase inhibitors retard the degradation of cAMP, elevating the intracellular concentration of this substance and augmenting myocardial contractility. In canine and porcine studies of bupivacaine-induced hypotension, the administration of amrinone was associated with a higher incidence of survival and a lower incidence of cardiac arrest than was epinephrine or placebo. 61, 62 On the other hand, amrinone can induce peripheral vasodilation, which would interfere with the maintenance of coronary perfusion pressure during resuscitation from cardiac arrest.
Lipid Therapy
In 1998, a set of experiments confirmed that pretreatment with lipid infusion increased the resistance of rats to bupivacaine-induced asystole. 63 In the first study, either a 30% lipid emulsion or saline was administered before the intravenous infusion of bupivacaine. In the second study, either lipid or saline was administered after asystole was induced by bolus doses of bupivacaine. In both prophylactic and therapeutic administrations, lipid emulsion was associated with significant increases in the lethal TOXICITY OF LOCAL ANESTHETICS 175 doses of bupivacaine 63 (Fig. 2) . The same researchers subsequently induced cardiac arrest in dogs with 10 mg/kg bupivacaine. After 10 minutes of unsuccessful closed chest compression, the animals were given either a 20% lipid emulsion or saline. Rescue treatment with lipid was associated with significant improvements in hemodynamic parameters, intramyocardial pH and PO 2 , and resuscitative success. 64 The efficacy of lipid in combating bupivacaine-induced cardiac toxicity is thought to lie in its ability to accelerate the washout of the LA from the myocardium. When added to a volume of blood, lipid emulsion will draw lipophilic drugs out of the hydrophilic plasma compartment. In vivo, this mechanism can, in turn, extract bupivacaine from the myocardium, thus promoting successful resuscitation. In addition, lipid infusion may help restore myocardial ATP stores depleted by bupivacaine intoxication. It has also been reported that inhibition of nitric oxide synthesis increases the susceptibility of rats to bupivacaine cardiotoxicity, whereas lipid emulsion accelerates nitric oxide production. Considering the established safety of lipid emulsions and the extreme or insurmountable problems encountered in the management of bupivacaine cardiotoxicity, it has been suggested that lipid therapy be initiated "at the earliest sign of severe local anesthetic-induced cardiac toxicity."
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Conclusion
Regional anesthesia can greatly enhance the comfort of our patients, but the LA drugs bear their own inherent risks. Longstanding assumptions such as the suitability of lidocaine and the unsuitability of 2-chloroprocaine for subarachnoid administration have been challenged. Systemic LA toxicity, always a concern, can be exceedingly difficult to reverse when bupivacaine is the offending agent. Levobupivacaine and ropivacaine may prove to be systemically safer options for long-acting local anesthesia, whereas unconventional approaches to resuscitation such as the infusion of lipid emulsion may enable otherwise catastrophic situations to be salvaged.
